C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care

Eur Heart J. 2013 May;34(17):1258-61. doi: 10.1093/eurheartj/eht022. Epub 2013 Feb 1.

Authors

Paul M Ridker¹, John J P Kastelein, Jacques Genest, Wolfgang Koenig

Affiliation

¹ Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital and Harvard Medical School, 900 Commonwealth Ave East, Boston, MA 02215, USA. pridker@partners.org

PMID: 23376447
DOI: 10.1093/eurheartj/eht022

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers / blood
C-Reactive Protein / metabolism*
Cardiovascular Diseases / prevention & control*
Cholesterol / blood*
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Randomized Controlled Trials as Topic
Reference Standards
Risk Assessment
Risk Factors

Substances

Biomarkers
Cholesterol, HDL
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
C-Reactive Protein
Cholesterol